Abdulsamet ERDEN, Özlem MORALOĞLU TEKİN, Atakan TANAÇAN, Ahmet OMMA, Seyit Ahmet EROL, Serpil ÜNLÜ, Hakan APAYDIN, Derya UYAN HENDEM, Orhan KÜÇÜKŞAHİN, İhsan ATEŞ, Dilek ŞAHİN, Şule GÖNCÜ AYHAN, Deniz OLUKLU

An evaluation of the results of convalescent plasma therapy applied to pregnant women diagnosed as COVID-19- positive in a pandemic center: A prospective cohort study

Background/aim: Convalescent plasma (CP) might be an additional treatment modality in COVID-19. The aim of this study was to compare CP-related clinical characteristics and perinatal outcomes in pregnant women with mild or moderate-severe COVID-19. Materials and methods: This prospective cohort study included 36 pregnant women (12 mild and 24 moderate-severe), who underwent CP therapy. The CP obtained from recently recovered donors was transfused to patients together with maximum supportive care and antiviral agents. The groups were then compared in respect of clinical characteristics, laboratory parameters, obstetric complications, and neonatal outcomes. Results: Significant differences were determined between the groups in respect of systemic corticosteroids in COVID-19 treatment (41.7%, 87.5%, p = 0.004), oxygen (O2) support (0%, 91.7%, p < 0.001), chest imaging (41.7%, 58.3%, p = 0.02), intensive care unit admission (0%, 20.8%, p = 0.03) and length of hospitalization (5.5 versus 9.5 days, p < 0.001). The O2 saturation levels before and after administration of CP were significantly lower in the moderate-severe COVID-19 group (p < 0.05). The O2 therapy time before and after administration of CP and total O2 therapy time were significantly lower in the mild COVID-19 group (p < 0.05). Platelet, plateletcrit and lymphocyte counts were significantly higher in both the mild and moderate-severe COVID-19 groups after treatment compared to the pretreatment values (p < 0.05). Conclusion: Although data on the results of CP treatment in pregnant women are somewhat limited, it has been suggested that early CP treatment may be associated with improvements in laboratory and ventilatory parameters in pregnant women with mild and moderatesevere COVID-19. Nevertheless, there is a need for further, randomized controlled studies on this subject with the inclusion of greater numbers of patients.

PDF

___

1. Chen N, Zhou M, Dong X, Qu J, Gong F et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. doi:10.1016/S0140-6736(20)30211-7
2. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Bioscience Trends. 2020;14(1):69-71. doi:10.5582/bst.2020.01020
3. Clark E, Guilpain P, Filip IL, Pansu N, Bihan CL et al. Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. British Journal of Haematology. 2020;190(3):e154-e156. doi:10.1111/bjh.16981
4. Ciftciler R, Ciftciler AE. Treatment modalities in COVID 19. Aksaray University Journal of Medical Sciences. 2021; 2(1): 20- 21.
5. Magallanes-Garza GI, Valdez-Alatorre C, Dávila-González D, Martínez-Reséndez MF, Sánchez-Salazar SS et al. Rapid improvement of a critically ill obstetric patient with SARSCoV-2 infection after administration of convalescent plasma. International Journal of Gynaecology and Obstetrics. 2021;152(3):439-441. doi:10.1002/ijgo.13467
6. Soleimani Z, Soleimani A. ADRS due to COVID-19 in midterm pregnancy: successful management with plasma transfusion and corticosteroids [published online ahead of print, 2020 Jul 26]. The Journal of Maternal-Fetal and Neonatal Medicine. 2020;1-4. doi:10.1080/14767058.2020.1797669
7. Anderson J, Schauer J, Bryant S, Graves CR. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report. Case Reports in Women’s Health. 2020;27:e00221. doi:10.1016/j.crwh.2020. e00221
8. Sahin D, Tanacan A, Erol SA, Anuk AT, Eyi EGY et al. A pandemic center’s experience of managing pregnant women with COVID-19 infection in Turkey: A prospective cohort study. International Journal of Gynaecology and Obstetrics. 2020;151(1):74-82. doi:10.1002/ijgo.13318
9. Sahin D, Tanacan A, Erol SA, Anuk AT, Yetiskin FDY et al. Updated experience of a tertiary pandemic center on 533 pregnant women with COVID-19 infection: A prospective cohort study from Turkey. International Journal of Gynaecology and Obstetrics. 2021;152(3):328-334. doi:10.1002/ijgo.13460
10. Tanacan A, Erol SA, Turgay B, Anuk AT, Secen EI et al. The rate of SARS-CoV-2 positivity in asymptomatic pregnant women admitted to hospital for delivery: Experience of a pandemic center in Turkey. European Journal of Obstetrics Gynecology and Reproductive Biology. 2020;253:31-34. doi:10.1016/j. ejogrb.2020.07.051
11. Selvi V. Convalescent Plasma: A Challenging Tool to Treat COVID-19 Patients-A Lesson from the Past and New Perspectives. BioMed Research International. 2020;2020:2606058. doi:10.1155/2020/2606058
12. Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmunity Reviews. 2020;19(7):102554. doi:10.1016/j.autrev.2020.102554
13. Duan K, Liu B, Li C, Zhang H, Yu T et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences of the United States of America. 2020;117(17):9490-9496. doi:10.1073/ pnas.2004168117
14. Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nature Medicine. 2020;26(11):1708-1713. doi:10.1038/s41591-020-1088-9
15. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. The Journal of Clinical Investigation. 2020;130(6):2757-2765. doi:10.1172/JCI138745
16. Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A et al. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. The New England Journal of Medicine. 2021;384(7):610-618. doi:10.1056/NEJMoa2033700
17. Tobian AAR, Shaz BH. Earlier the better: convalescent plasma. Blood. 2020;136(6):652-654. doi:10.1182/blood.2020007638
18. Moniuszko-Malinowska A, Czupryna P, Zarębska-Michaluk D, Tomasiewicz K, Pancewicz S et al. Convalescent Plasma Transfusion for the Treatment of COVID-19-Experience from Poland: A Multicenter Study. Journal of Clinical Medicine. 2020;10(1):28. doi:10.3390/jcm10010028
19. Roberts DJ, Miflin G, Estcourt L. Convalescent plasma for COVID-19: Back to the future. Transfusion Medicine. 2020;30(3):174-176. doi:10.1111/tme.12700
20. Sun B, Feng Y, Mo X, Zheng P, Wang Q et al. Kinetics of SARSCoV-2 specific IgM and IgG responses in COVID-19 patients. Emerging Microbes and Infections. 2020;9(1):940-948. doi:10. 1080/22221751.2020.1762515
21. Avendaño-Solá C, Ramos-Martínez A, Muñez-Rubio E, RuizAntorán B, Malo de Molina R et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. The Journal of Clinical Investigation. 2021;131(20):e152740. doi:10.1172/ JCI152740B
22. Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial ThreeMonth Experience. medRxiv. 2020;2020.08.12.20169359. doi:10.1101/2020.08.12.20169359
23. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B et al. Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer AntiSevere Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2) Spike Protein IgG. The American Journal of Pathology. 2021;191(1): 90-107. doi:10.1016/j.ajpath.2020.10.008
24. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020; 371:m3939. doi:10.1136/bmj.m3939
25. Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature Medicine. 2021; 27(4): 622-625. doi:10.1038/s41591-021-01285-x
26. Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. The Journal of Clinical Investigation. 2020;130(9): 4791-4797. doi:10.1172/JCI140200
27. Nguyen FT, van den Akker T, Lally K, Lam H, Lenskaya V et al. Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2. Transfusion. 2021;61(1):78- 93. doi:10.1111/trf.16177
28. Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clinic Proceedings. 2020;95(9):1888-1897. doi:10.1016/j.mayocp.2020.06.028
29. Grisolia G, Franchini M, Glingani C, Inglese F, Garuti M et al. Convalescent plasma for coronavirus disease 2019 in pregnancy: a case report and review. American Journal of Obstetrics and Gynecology MFM. 2020;2(3):100174. doi:10.1016/j.ajogmf.2020.100174
30. Zhang B, Liu S, Tan T, Huang W, Dong Y et al. Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Chest. 2020;158(1):e9-e13. doi:10.1016/j.chest.2020.03.039
31. Salazar E, Perez KK, Ashraf M, Chen J, Castillo B et al. Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. The American Journal of Pathology. 2020;190(8):1680-1690. doi:10.1016/j.ajpath.2020.05.014
32. Khamis F, Al-Zakwani I, Al Hashmi S, Al Dowaiki S, Al Bahrani M et al. Therapeutic plasma exchange in adults with severe COVID-19 infection. International Journal of Infectious Diseases. 2020;99:214-218. doi:10.1016/j.ijid.2020.06.064
33. Xia X, Li K, Wu L, Wang Z, Zhu M et al. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood. 2020;136(6):755-759. doi:10.1182/blood.2020007079